Literature DB >> 22642647

Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against influenza virus infection.

T Maruo1, Y Gotoh, H Nishimura, S Ohashi, T Toda, K Takahashi.   

Abstract

AIMS: To evaluate the protective effects of oral administration of milk fermented with a Lactococcus strain against influenza virus (IFV) infection in a mouse model. METHODS AND
RESULTS: Milk fermented with exopolysaccharide-producing Lactococcus lactis subsp. cremoris (L. cremoris) FC was orally administered to BALB/c mice for 12 days. Mice were intranasally infected with IFV A/New Caledonia/20/99 (H1N1) on day 8, and survival was determined for 14 days after IFV infection. Survival rate and body weight loss after IFV infection in the L. cremoris FC fermented milk-administered group were significantly improved compared with those in the control group. In the unfermented milk-administered group, survival rate was not improved, whereas body weight loss was slightly improved compared with that in the control group. The mean virus titre in the lung of the L. cremoris FC fermented milk-administered group 3 days after infection was significantly decreased compared with that in the control group.
CONCLUSIONS: These results suggest that oral administration of milk fermented with L. cremoris FC protects mice against IFV infection. SIGNIFICANCE AND IMPACT OF THE STUDY: These results demonstrate that oral administration of milk fermented with exopolysaccharide-producing Lactococcus strains might protect host animals against IFV infection.
© 2012 The Authors. Letters in Applied Microbiology © 2012 The Society for Applied Microbiology.

Entities:  

Mesh:

Year:  2012        PMID: 22642647     DOI: 10.1111/j.1472-765X.2012.03270.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  11 in total

Review 1.  Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies.

Authors:  Haider Abdul-Lateef Mousa
Journal:  J Evid Based Complementary Altern Med       Date:  2016-04-06

Review 2.  Probiotics in respiratory virus infections.

Authors:  L Lehtoranta; A Pitkäranta; R Korpela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-18       Impact factor: 3.267

Review 3.  Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies.

Authors:  Hai Yun Shi; Xi Zhu; Wei Lin Li; Joyce W Y Mak; Sunny H Wong; Sheng Tao Zhu; Shui Long Guo; Francis K L Chan; Shu Tian Zhang; Siew C Ng
Journal:  Eur J Nutr       Date:  2021-04-14       Impact factor: 4.865

4.  A meta-analysis reveals the effectiveness of probiotics and prebiotics against respiratory viral infection.

Authors:  Fangyan Wang; Binhui Pan; Sheng Xu; Zhihua Xu; Tiaotiao Zhang; Qihao Zhang; Yifan Bao; Yingwei Wang; Jiamin Zhang; Changlong Xu; Xiangyang Xue
Journal:  Biosci Rep       Date:  2021-03-26       Impact factor: 3.840

Review 5.  The efficacy of probiotics on virus titres and antibody production in virus diseases: A systematic review on recent evidence for COVID-19 treatment.

Authors:  Shahrzad Mirashrafi; Amir Reza Moravejolahkami; Zakiyeh Balouch Zehi; Mohammad Ali Hojjati Kermani; Nimah Bahreini-Esfahani; Mohsen Haratian; Marjan Ganjali Dashti; Meraj Pourhossein
Journal:  Clin Nutr ESPEN       Date:  2021-10-23

6.  A Novel Immunobiotics Bacteroides dorei Ameliorates Influenza Virus Infection in Mice.

Authors:  Liqiong Song; Yuanming Huang; Guoxing Liu; Xianping Li; Yuchun Xiao; Chang Liu; Yue Zhang; Jintong Li; Jianguo Xu; Shan Lu; Zhihong Ren
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

7.  Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K.

Authors:  Takumu Hasebe; Nobuhiro Ueno; Mark W Musch; Anuradha Nadimpalli; Atsushi Kaneko; Noriko Kaifuchi; Junko Watanabe; Masahiro Yamamoto; Toru Kono; Yuhei Inaba; Mikihiro Fujiya; Yutaka Kohgo; Eugene B Chang
Journal:  Pharmacol Res Perspect       Date:  2016-02-10

Review 8.  Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy.

Authors:  Dana P Cook; Conny Gysemans; Chantal Mathieu
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

Review 9.  New lactic acid bacteria for skin health via oral intake of heat-killed or live cells.

Authors:  Hiromi Kimoto-Nira
Journal:  Anim Sci J       Date:  2018-04-26       Impact factor: 1.749

Review 10.  The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?

Authors:  Mehran Mahooti; Seyed Mohammad Miri; Elahe Abdolalipour; Amir Ghaemi
Journal:  Microb Pathog       Date:  2020-08-18       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.